To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment Subjects
Status:
COMPLETED
Trial end date:
2025-08-12
Target enrollment:
Participant gender:
Summary
This is an open, open-label, parallel, single-dose, phase I clinical study designed to evaluate the pharmacokinetic (PK) profile of TQ05105 tablet in patients with renal impairment after a single dose, and to evaluate the urinary excretion of the drug in these patients after a single dose, as well as to evaluate the safety of the drug in these patients after a single dose.